Evidence for improving the therapeutic response to ixekizumab: more than just a statistic

A Borghi¹

Affiliations

Comment

A Borghi. Br J Dermatol. 2018 Jun.

. 2018 Jun;178(6):1237-1238.

doi: 10.1111/bjd.16653.

A Borghi¹

¹ Department of Medical Sciences, Section of Dermatology and Infectious Diseases, University of Ferrara, Via L. Ariosto 35, 44121, Ferrara, Italy.

No abstract available

Comment on

Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P).
Langley RG, Papp K, Gooderham M, Zhang L, Mallinckrodt C, Agada N, Blauvelt A, Foley P, Polzer P; of the IXORA-P Investigators. Langley RG, et al. Br J Dermatol. 2018 Jun;178(6):1315-1323. doi: 10.1111/bjd.16426. Epub 2018 May 15. Br J Dermatol. 2018. PMID: 29405255 Clinical Trial.